- Home
- PRTA vs GEVO Comparison
PRTA vs GEVO Comparison
Compare PRTA & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- GEVO
- Stock Information
- Founded
- PRTA 2012
- GEVO 2005
- Country
- PRTA Ireland
- GEVO United States
- Employees
- PRTA N/A
- GEVO N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- PRTA Health Care
- GEVO Industrials
- Exchange
- PRTA Nasdaq
- GEVO Nasdaq
- Market Cap
- PRTA 472.1M
- GEVO 418.4M
- IPO Year
- PRTA N/A
- GEVO 2011
- Fundamental
- Price
- PRTA $8.20
- GEVO $1.73
- Analyst Decision
- PRTA Buy
- GEVO Buy
- Analyst Count
- PRTA 10
- GEVO 2
- Target Price
- PRTA $14.86
- GEVO $7.58
- AVG Volume (30 Days)
- PRTA 1.2M
- GEVO 9.3M
- Earning Date
- PRTA 08-04-2025
- GEVO 08-11-2025
- Dividend Yield
- PRTA N/A
- GEVO N/A
- EPS Growth
- PRTA N/A
- GEVO N/A
- EPS
- PRTA N/A
- GEVO N/A
- Revenue
- PRTA $10,341,000.00
- GEVO $80,187,000.00
- Revenue This Year
- PRTA N/A
- GEVO $909.99
- Revenue Next Year
- PRTA $389.77
- GEVO $22.37
- P/E Ratio
- PRTA N/A
- GEVO N/A
- Revenue Growth
- PRTA N/A
- GEVO 341.75
- 52 Week Low
- PRTA $4.32
- GEVO $0.67
- 52 Week High
- PRTA $22.83
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- PRTA 58.73
- GEVO 57.77
- Support Level
- PRTA $8.05
- GEVO $1.54
- Resistance Level
- PRTA $8.73
- GEVO $1.86
- Average True Range (ATR)
- PRTA 0.38
- GEVO 0.14
- MACD
- PRTA -0.05
- GEVO 0.01
- Stochastic Oscillator
- PRTA 47.62
- GEVO 31.15
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.